COVID-19 and type 2 diabetes mellitus: implications in pancreatic beta cells

Authors

  • Ivonne Grisel Sánchez-Cervantes <p>Universidad Nacional Aut&oacute;noma de M&eacute;xico, Facultad de Medicina, Unidad de Microscop&iacute;a. Ciudad de M&eacute;xico, M&eacute;xico.</p> http://orcid.org/0000-0001-6918-1354
  • Ignacio González-Sánchez <p>Universidad Nacional Aut&oacute;noma de M&eacute;xico, Facultad de Qu&iacute;mica, Departamento de Biolog&iacute;a. Ciudad de M&eacute;xico, M&eacute;xico.</p> http://orcid.org/0000-0003-4282-5062
  • Irma Elena López-Martínez <p>Universidad Nacional Aut&oacute;noma de M&eacute;xico, Facultad de Medicina, Unidad de Microscop&iacute;a. Ciudad de M&eacute;xico, M&eacute;xico.</p> http://orcid.org/0000-0001-8510-4519
  • Elsa Liliana Aguirre-Benítez <p>Universidad Nacional Aut&oacute;noma de M&eacute;xico, Facultad de Medicina, Departamento de Embriolog&iacute;a y Gen&eacute;tica. Ciudad de M&eacute;xico, M&eacute;xico.</p> http://orcid.org/0000-0001-5432-7445
  • Cristina Coronel-Cruz <p>Universidad Nacional Aut&oacute;noma de M&eacute;xico, Facultad de Medicina, Departamento de Biolog&iacute;a Celular y Tisular. Ciudad de M&eacute;xico, M&eacute;xico.</p> http://orcid.org/0000-0003-2405-6060

DOI:

https://doi.org/10.5281/zenodo.10712093

Keywords:

SARS-CoV-2, Insulin-Secreting Cells, Diabetes Mellitus, Type 2, COVID-19

Abstract

The prevalence of chronic metabolic diseases in Mexico is high, being type 2 Diabetes mellitus (T2DM) as the most common disease. Several studies have shown that, compared with healthy individuals, patients with T2DM suffer a higher severity and mortality of Coronavirus disease 2019 (COVID-19). Therefore, it is important to the knowledge of the bidirectional relationship between these diseases. T2DM can increase SARS-CoV-2 virus pathogenicity in part due to metabolic disturbance. As a result, COVID-19 susceptibility and severity rise in diabetic individuals, which makes them a high-risk population. On the other hand, the infection caused by SARS-CoV-2 can lead individuals to hyperglycemia or new-onset diabetes. In order to understand the relationship between COVID-19 and T2DM, this review aims to emphasize the tropism of the SARS-CoV-2 virus to pancreatic beta-cells, as well as the physiologic effects of these.

Downloads

Download data is not yet available.

Author Biographies

  • Ivonne Grisel Sánchez-Cervantes, <p>Universidad Nacional Aut&oacute;noma de M&eacute;xico, Facultad de Medicina, Unidad de Microscop&iacute;a. Ciudad de M&eacute;xico, M&eacute;xico.</p>

    Técnico Académica Titular A

  • Ignacio González-Sánchez, <p>Universidad Nacional Aut&oacute;noma de M&eacute;xico, Facultad de Qu&iacute;mica, Departamento de Biolog&iacute;a. Ciudad de M&eacute;xico, M&eacute;xico.</p>

    Profesor de Asignatura A

  • Irma Elena López-Martínez, <p>Universidad Nacional Aut&oacute;noma de M&eacute;xico, Facultad de Medicina, Unidad de Microscop&iacute;a. Ciudad de M&eacute;xico, M&eacute;xico.</p>

    Técnico Académica Titular C

  • Elsa Liliana Aguirre-Benítez, <p>Universidad Nacional Aut&oacute;noma de M&eacute;xico, Facultad de Medicina, Departamento de Embriolog&iacute;a y Gen&eacute;tica. Ciudad de M&eacute;xico, M&eacute;xico.</p>

    Técnico Académica Titular B

  • Cristina Coronel-Cruz, <p>Universidad Nacional Aut&oacute;noma de M&eacute;xico, Facultad de Medicina, Departamento de Biolog&iacute;a Celular y Tisular. Ciudad de M&eacute;xico, M&eacute;xico.</p>

    Profesora Asociada C, T.C.

    Departamento de Biología Celular y Tisular

    Facultad de Medicina, UNAM.

References

 

Tabacof L, Tosto-Mancuso J, Wood J, et al. Post-acute COVID-19 Syndrome Negatively Impacts Physical Function, Cognitive Function, Health-Related Quality of Life, and Participation. Am J Phys Med Rehabil. 2022;101(1):48-52. doi: 10.1097/PHM.0000000000001910.

Li J, He X, Yuan Y, et al. Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. Am J Infect Control. 2021;49(1):82-9. doi: 10.1016/j.ajic.2020.06.008.

Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813-22. doi: 10.1016/S2213-8587(20)30272-2.

Steenblock C, Hassanein M, Khan EG, et al. Diabetes and COVID-19: Short- and Long-Term Consequences. Horm Metab Res. 2022;54(8):503-9. doi: 10.1055/a-1878-9566.

Denova-Gutierrez E, Lopez-Gatell H, Alomia-Zegarra JL, et al. The Association of Obesity, Type 2 Diabetes, and Hypertension with Severe Coronavirus Disease 2019 on Admission Among Mexican Patients. Obesity (Silver Spring). 2020;28(10):1826-32. doi: 10.1002/oby.22946.

Jedrzejak AP, Urbaniak EK, Wasko JA, et al. Diabetes and SARS-CoV-2-Is There a Mutual Connection? Front Cell Dev Biol. 2022;10:913305. doi: 10.3389/fcell.2022.913305.

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80. doi: 10.1016/j.cell.2020.02.052.

V'Kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155-70. doi: 10.1038/s41579-020-00468-6.

Mu J, Fang Y, Yang Q, et al. SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2. Cell Discov. 2020;6:65. doi: 10.1038/s41421-020-00208-3.

Memon B, Abdelalim EM. ACE2 function in the pancreatic islet: Implications for relationship between SARS-CoV-2 and diabetes. Acta Physiol (Oxf). 2021;233(4):e13733. doi: 10.1111/apha.13733.

Fignani D, Licata G, Brusco N, et al. SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic beta-Cells and in the Human Pancreas Microvasculature. Front Endocrinol (Lausanne). 2020;11:596898. doi: 10.3389/fendo.2020.596898.

Liu F, Long X, Zhang B, et al. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. Clin Gastroenterol Hepatol. 2020;18(9):2128-30. doi: 10.1016/j.cgh.2020.04.040.

Coate KC, Cha J, Shrestha S, et al. SARS-CoV-2 Cell Entry Factors ACE2 and TMPRSS2 Are Expressed in the Microvasculature and Ducts of Human Pancreas but Are Not Enriched in beta Cells. Cell Metab. 2020;32(6):1028-40. doi: 10.1016/j.cmet.2020.11.006.

Hikmet F, Mear L, Edvinsson A, et al. The protein expression profile of ACE2 in human tissues. Mol Syst Biol. 2020;16(7):e9610. doi: 10.15252/msb.20209610.

Geravandi S, Mahmoudi-Aznaveh A, Azizi Z, et al. SARS-CoV-2 and pancreas: a potential pathological interaction? Trends Endocrinol Metab. 2021;32(11):842-5. doi: 10.1016/j.tem.2021.07.004.

Wu CT, Lidsky PV, Xiao Y, et al. SARS-CoV-2 infects human pancreatic beta cells and elicits beta cell impairment. Cell Metab. 2021;33(8):1565-76 e5. doi: 10.1016/j.cmet.2021.05.013.

Hayden MR. An Immediate and Long-Term Complication of COVID-19 May Be Type 2 Diabetes Mellitus: The Central Role of beta-Cell Dysfunction, Apoptosis and Exploration of Possible Mechanisms. Cells. 2020;9(11). doi: 10.3390/cells9112475.

Hernandez-Ochoa B, Ortega-Cuellar D, Gonzalez-Valdez A, et al. COVID-19 in G6PD-deficient Patients, Oxidative Stress, and Neuropathology. Curr Top Med Chem. 2022;22(16):1307-25. doi: 10.2174/1568026622666220516111122.

Olagnier D, Farahani E, Thyrsted J, et al. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Nat Commun. 2020;11(1):4938. doi: 10.1038/s41467-020-18764-3.

Geca T, Wojtowicz K, Guzik P, et al. Increased Risk of COVID-19 in Patients with Diabetes Mellitus-Current Challenges in Pathophysiology, Treatment and Prevention. Int J Environ Res Public Health. 2022;19(11). doi: 10.3390/ijerph19116555.

Ramasamy S, Subbian S. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis. Clin Microbiol Rev. 2021;34(3). doi: 10.1128/CMR.00299-20.

Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-9. doi: 10.1172/JCI137244.

Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-2. doi: 10.1016/S2213-2600(20)30076-X.

Tan M, Liu Y, Zhou R, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology. 2020;160(3):261-8. doi: 10.1111/imm.13223.

Shao S, Yang Q, Pan R, et al. Interaction of Severe Acute Respiratory Syndrome Coronavirus 2 and Diabetes. Front Endocrinol (Lausanne). 2021;12:731974. doi: 10.3389/fendo.2021.731974.

Sen S, Chakraborty R, Kalita P, et al. Diabetes mellitus and COVID-19: Understanding the association in light of current evidence. World J Clin Cases. 2021;9(28):8327-39. doi: 10.12998/wjcc.v9.i28.8327.

Yang L, Han Y, Nilsson-Payant BE, et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell. 2020;27(1):125-36 e7. doi: 10.1016/j.stem.2020.06.015.

Muller JA, Gross R, Conzelmann C, et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab. 2021;3(2):149-65. doi: 10.1038/s42255-021-00347-1.

Tang X, Uhl S, Zhang T, et al. SARS-CoV-2 infection induces beta cell transdifferentiation. Cell Metab. 2021;33(8):1577-91 e7. doi: 10.1016/j.cmet.2021.05.015.

Kim SH, Arora I, Hsia DS, et al. New-Onset Diabetes after COVID-19. J Clin Endocrinol Metab. 2023. doi: 10.1210/clinem/dgad284.

Montefusco L, Ben Nasr M, D'Addio F, et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab. 2021;3(6):774-85. doi: 10.1038/s42255-021-00407-6.

Pal R, Banerjee M, Yadav U, et al. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: A systematic review of literature. Diabetes Metab Syndr. 2020;14(6):1563-9. doi: 10.1016/j.dsx.2020.08.015.

Zhu Z, Mao Y, Chen G. Predictive value of HbA1c for in-hospital adverse prognosis in COVID-19: A systematic review and meta-analysis. Prim Care Diabetes. 2021;15(6):910-7. doi: 10.1016/j.pcd.2021.07.013.

Zhu L, She ZG, Cheng X, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020;31(6):1068-77 e3. doi: 10.1016/j.cmet.2020.04.021.

Gangadharan C, Ahluwalia R, Sigamani A. Diabetes and COVID-19: Role of insulin resistance as a risk factor for COVID-19 severity. World J Diabetes. 2021;12(9):1550-62. doi: 10.4239/wjd.v12.i9.1550.

Downloads

Published

2024-03-27

Issue

Vol. 62 No. 2 (2024): March-April

Section

Review Article

License

Copyright (c) 2024 Revista Médica del Instituto Mexicano del Seguro Social

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.